Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients

Blood Purification

Volumn 36, Issue 1, 2013, Pages 29-36

  Nishio, Angie ^a   Chhatkuli, Bed P ^a   Ma, Jennie Z ^a   Kalantari, Kambiz ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Anemia; Darbepoetin alfa; End stage renal disease; Erythropoietin; Hyporesponsiveness; Mortality

Indexed keywords

ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARATHYROID HORMONE; SERUM ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VASCULAR ACCESS; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; COMORBIDITY; CONFERENCE PAPER; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; END STAGE RENAL DISEASE; HAZARD RATIO; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HYPERTENSION; MIDDLE AGED; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

AGED; ANEMIA; CAUSE OF DEATH; COMORBIDITY; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84878345875     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000350583     Document Type: Article

References (31)

1. Besarab A: Anemia and iron management. Semin Dial 2011; 24: 498-503.
2. Bradbury BD, Danese MD, Gleeson M, Critchlow CW: Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dl. Clin J Am Soc Nephrol 2009; 4: 630-637.
3. Weinhandl ED, Gilbertson DT, Collins AJ: Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Am J Nephrol 2011; 34: 298-308.
4. Seliger SL, Zhang AD, Weir MR, et al: Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011; 80: 288-294.
5. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619. (Pubitemid 29117643)
6. Macdougall IC, Lewis NP, Saunders MJ, et al: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489-493. (Pubitemid 20073052)
7. Marsh JT, Brown WS, Wolcott D, et al: rHu-EPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155-163.
8. Wizemann V, Kaufmann J, Kramer W: Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-165.
9. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc Nephrol 2000; 11: 335-342. (Pubitemid 30064857)
10. Drueke TB, Locatelli F, Clyne N, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
11. Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
12. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)
13. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
14. Streja E, Kovesdy CP, Greenland S, et al: Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736.
15. Szczech LA, Barnhart HX, Inrig JK, et al: Secondary analysis of the CHOIR trial epoetinalpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
16. Johnson DW, Pollock CA, Macdougall IC: Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007; 12: 321-330.
17. Kilpatrick RD, Critchlow CW, Fishbane S, et al: Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
18. Fukuma S, Yamaguchi T, Hashimoto S, et al: Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2012; 59: 108-116.
19. Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M: Renal anemia of inflammation: the name is self-explanatory. Blood Purif 2011; 32: 220-225.
20. Coyne DW: Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011; 80: 240-244.
21. Barany P, Divino Filho JC, Bergstrom J: High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-568. (Pubitemid 27155278)
22. de Lurdes Agostinho Cabrita A, Pinho A, Malho A, et al: Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol 2011; 43: 835-840.
23. Gunnell J, Yeun JY, Depner TA, Kaysen GA: Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63-72. (Pubitemid 29031210)
24. Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876. (Pubitemid 39445919)
25. Solomon SD, Uno H, Lewis EF, et al: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
26. Panichi V, Rosati A, Bigazzi R, et al: Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
27. Bradbury BD, Wang O, Critchlow CW, et al: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51: 62-70. (Pubitemid 350296516)
28. Bohlius J, Schmidlin K, Brillant C, et al: Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.
29. Corwin HL, Gettinger A, Fabian TC, et al: Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976. (Pubitemid 47367076)
30. Singh AK: Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int 2011; 80: 569-571.
31. Strippoli GF: Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010; 11: 70.